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Abstract
The observation that Alzheimer’s disease (AD) patients with similar and even identical genetic backgrounds often present
with heterogeneous pathologies has prompted the hypothesis that epigenetics may contribute to AD. While the study of
epigenetics encompasses a variety of modifications including histone modifications and non-coding RNAs, much of the
research on how epigenetics might impact AD pathology has been focused on DNA methylation. To this end, several studies
have characterized DNA methylation alterations in various brain regions of individuals with AD, with conflicting results.
This review examines the results of studies analyzing both global and gene-specific DNA methylation changes in AD and
also assesses the results of studies analyzing DNA hydroxymethylation in patients with AD.
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Introduction to dementia and Alzheimer’s
disease
Dementia, an age-related neurodegenerative disorder charac-
terized by progressive cognitive decline, affects 35.6 million
people worldwide and is becoming an increasingly relevant
concern as the population ages [1, 2]. It is estimated that the
prevalence of dementia is expected to double every 20 years
such that 115.4 million individuals will have dementia by 2050
[2]. In terms of its economic burden, the total estimated cost of
dementia worldwide was $604 billion U.S. dollars in 2010 [3]; in
the United States alone, the annual societal cost of dementia
was between $159 billion and $215 billion [1]. Moreover, predic-
tive modeling suggests that there will be a cost increase of
almost 80% per adult by 2040 [1]. In light of its substantial soci-
etal and economic burden, there has been a strong push within
the research community to better understand the etiology of
dementia.
Dementia is a broad term encompassing a wide span of neu-
rodegenerative disorders including Alzheimer’s disease (AD),
vascular dementia and dementia with Lewy bodies [4]. AD is the
most common type of dementia, accounting for 50–80% of all
dementia cases [5–7]. Currently, AD affects 5.4 million
Americans, yet this number is expected to increase to 13.8 mil-
lion by 2050 as the population ages [5]. As of 2013, AD was the
sixth leading cause of death in the United States behind heart
disease, cancer, lower respiratory disease, unintentional injury
and stroke [8]. Strikingly, between 2000 and 2013, deaths from
stroke and heart disease decreased by 23 and 14%, respectively,
whereas deaths from AD increased by 71%, highlighting the
necessity to better understand the etiology and pathogenesis of
AD [5]. Because AD is the most common type of dementia, this
review will focus specifically on AD.
AD is characterized by cerebral extracellular amyloid-b (Ab)
plaques and intracellular neurofibrillary tangles (NFTs) [9]. The
sequential cleavage of amyloid precursor protein (APP) by the
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membrane-bound proteins b-secretase and c-secretase gener-
ates amyloidogenic Ab peptides, which accumulate within the
extracellular space to form insoluble Ab plaques [10, 11]. In
addition, APP also can be cleaved by a-secretase and then again
by c-secretase, resulting in the production of soluble, nonamy-
loidogenic Ab peptides. Besides Ab plaques, intracellular NFTs
are the other primary pathological hallmark of AD. These tan-
gles are created by hyperphosphorylation of microtubule-
associated protein tau (MAPT), and the number of NFTs in the
neocortex is positively correlated with the severity of dementia
[12]. The presence and severity of Ab plaques and NFTs within
the brain are often used for postmortem neuropathological
assessment of individuals diagnosed with AD [13].
AD is classified as early-onset AD (EOAD) or late-onset AD
(LOAD) [14, 15]. EOAD occurs in individuals younger than age 65
but may manifest as early as age 40 or 50 [16]. In addition, if
EOAD coincides with genetic mutations in APP, presenilin-1
(PSEN1) or presenilin-2 (PSEN2), the latter two of which code for
proteins that make up the main catalytic component of c-secre-
tase, the patient is diagnosed with familial AD. In this case,
multiple generations within a family can be affected. EOAD is
relatively rare and accounts for <10% of all AD cases [17]. LOAD,
on the other hand, which occurs in individuals older than age
65, is more common yet has no clear genetic association or
cause [18]. Despite its substantial socioeconomic burden, the
etiology of LOAD has not been elucidated in part due to its com-
plex pathogenesis and presentation.
Introduction to epigenetics
Recent research suggests that epigenetic factors often have an
impact on chronic diseases including cancer and AD [19–22].
Although there is no single, universally accepted definition of
epigenetics, many definitions touch upon the following compo-
nents [23–25]: (i) heritability, defined as the ability of a dividing
cell to pass epigenetic marks to its daughter cells; (ii) preserva-
tion of DNA sequence, in which the 50 to 30 order of nucleotides
remains unchanged; (iii) transcriptional regulation, whereby
epigenetic changes influence the transcription of genes and
therefore the phenotype of the cell; and (iv) stability, defined as
the maintenance of epigenetic modifications over time [26].
The number of studies examining epigenetic mechanisms
has risen dramatically as big-data genomics has gained popu-
larity. With this increased focus, the question of the stability of
epigenetic modifications has become a highly debated topic. It
was long thought that epigenetic marks were stable throughout
a lifetime [27]. However, it is now known that epigenetic modifi-
cations are dynamic, and as a result, research has begun to
focus on how environmental exposures can alter the epigenetic
landscape [24, 28–31]. Although epigenetics is a broad term
encompassing DNA methylation, histone modifications and
non-coding RNA, this review will focus specifically on DNA
methylation in AD; histone modifications and non-coding RNA
have been reviewed in detail elsewhere [32–36].
DNAmethylation
DNA methyltransferase (DNMT) enzymes, of which DNMT1,
DNMT3A and DNMT3B are best characterized [37, 38], catalyze
the transfer of a methyl group from S-adenosylmethionine to
DNA. The product of this reaction, S-adenosylhomocysteine, is
then converted back to S-adenosylmethionine through a series
of reactions as part of the one-carbon metabolism cycle [39].
Importantly, an elevation in plasma homocysteine, an
intermediate in this cycle, is associated with a greater risk for
developing dementia and AD [40–42], thus implicating DNA
methylation and alterations in one-carbon metabolism with AD
pathogenesis [43–47].
In mammals, DNA methylation primarily occurs on cytosine
residues of cytosine-guanine (CpG) dinucleotides and functions
to modulate gene expression [22, 48]. Canonically, DNA methyl-
ation is associated with reduced gene expression [49], yet recent
evidence suggests that the impact of DNA methylation on gene
expression is dependent upon its context within the genome
[50]. Though 5-methylcytosine (5mC) is the most abundant
modified base in the mammalian genome, recent studies have
identified additional modified bases such as N6-methyladenine
(N6mA) and 5-formylcytosine (5fC). N6mA, though prevalent in
prokaryotes, was thought to be absent in eukaryotes. In 2015,
researchers identified N6mA in three eukaryotic species: green
algae [51] (Chlamydomonas reinhardtii), nematodes [52]
(Caenorhabditis elegans) and fruit flies [53] (Drosophila mela-
nogaster), and in 2016, researchers characterized the existence
of N6mA in mouse embryonic stem cells [54]. The results of
these studies show that there is large variation in both the prev-
alence of this modification and its effect on gene expression
across eukaryotic species. 5fC was originally thought to be an
intermediate in enzyme-mediated DNA demethylation. Recent
studies suggest, however, that 5fC can be a stable DNA modifi-
cation that affects gene expression by altering the structure of
the DNA double helix [55–57]. Despite the progress gained by
these pioneering studies, knowledge of these modified bases is
still incomplete, and more research is needed to further charac-
terize their distribution and function.
For the purposes of this review, the term “global” DNA meth-
ylation describes the average percent methylation across the
entire genome. The term “gene-specific” DNA methylation, on
the other hand, refers to the average percent methylation
within a specific gene. Global DNA methylation, although useful
in that it provides an over-arching picture of methylation status
in a sample, is sometimes misleading as the proportion of genes
with significant alterations in DNA methylation to genes with
insignificant DNA methylation differences is generally very
small [58, 59]. Gene-specific DNA methylation, however, is able
to detect these hidden significant DNA methylation differences.
In studies on DNA methylation in AD, global DNA methylation
is often assessed via antibody-based methods such as immuno-
histochemistry, while gene-specific DNA methylation is ana-
lyzed using array-based methods such as Illumina’s Infinium
HumanMethylation450 BeadChip array. High-throughput tech-
niques utilizing bisulfite conversion are used to measure both
global and gene-specific DNA methylation.
DNA hydroxymethylation
The recent surge of interest in DNA hydroxymethylation began
with the publication of two papers in 2009 characterizing this
modification in separate systems: cerebellar purkinje neurons
and mouse embryonic stem cells [60, 61]. In contrast with the
relatively constant tissue distribution of 5mC, there is substan-
tial variation in the tissue distribution of 5-hydroxymethylcyto-
sine (5hmC). It is most abundant within the central nervous
system, with the highest percentage of 5hmC found within the
cerebral cortex, followed closely by the brainstem, spinal cord
and cerebellum [62]. In addition to the central nervous system,
5hmC is also present at lower levels in the heart, kidney,
liver, muscle and lung [62]. Ten-eleven translocation enzymes
oxidize the 5-methyl group on methylated cytosines to a
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5-hydroxymethyl group [63]. Despite a growing number of stud-
ies on the subject, the function of 5hmC is currently unknown.
It is hypothesized to either be an intermediate in active DNA
demethylation or be involved in gene regulation. More specifi-
cally, 5hmC within gene bodies is positively correlated with
gene expression. Although it is still unclear what the mecha-
nism behind this correlation is, it is thought to be due to the
association of 5hmC with histone marks H3K4me1 and
H3K27ac, both of which are markers of active promoters and
enhancers [64–66].
RNAmodifications
Of the various RNA-related chemical modifications found in
eukaryotic cells, most have been identified in rRNAs and tRNAs.
They have been shown to play a role in altering the structure
and function of mature RNAs to influence gene expression
[67, 68]. Reversible mRNA modifications, on the other hand,
have not been seriously studied until recently [69]. N6-methyla-
denosine (m6A), the most abundant of these modifications, was
the first to be discovered [70–72]. Initial studies in mammalian
cells using RNA immunoprecipitation followed by high-
throughput sequencing demonstrate that m6A is highly
enriched around stop codons and within long internal exons
and may function to affect gene expression [73, 74]. Since the
discovery of m6A, other dynamic RNA modifications such as
pseudouridine and N1-methyladenosine have been identified,
though more research is necessary to determine the mecha-
nisms by which these modifications influence gene expression
[75–79]. The information garnered thus far on RNA modifica-
tions is summarized in numerous review articles [67, 68].
Importantly, epigenetic mechanisms do not work in isola-
tion [80, 81]. Rather, they often work together to bring about
changes in gene expression and therefore phenotype. For exam-
ple, methyl-CpG-binding domain proteins (MBD2) bind to
methylated cytosines and recruit methyl-CpG binding protein 1
(MeCP1) complexes. Among other proteins, the MeCP1 complex
includes a nucleosome remodeling protein with a histone
deacetylase core [82]. Together, these proteins act to silence
that particular region of the genome. Recent studies suggest
that there are various types of epigenetic alterations associated
with the pathophysiology of AD, including alterations in DNA
methylation [17, 83, 84]. This review will focus on evidence con-
cerning the association between DNA methylation alterations
and AD.
Global DNAmethylation alterations in AD
Due to the heterogeneous clinical presentation of AD in patients
with very similar and sometimes identical genetic backgrounds,
it has been hypothesized that epigenetics may contribute to the
pathology of AD. The study of identical twins has classically
been used to separate the effect of genetics and environment.
In 2009, Mastroeni et al. [85] analyzed DNA methylation in a pair
of monozygotic twins discordant for AD. Using immunohisto-
chemical methods to detect 5mC, the authors found that global
DNA methylation within the anterior temporal neocortex and
the superior frontal gyrus was significantly decreased in the
twin with AD compared with the neurologically normal, non-
demented twin. Interestingly, although both twins were chemi-
cal engineers with similar levels of education, the AD twin
worked extensively with pesticides whereas the non-demented
twin did not, suggesting that work-related pesticide exposure
could have contributed to the development of AD. Thus, the
results of this study indicate that not only genetic mutations
but also environmental influences can affect AD presentation.
Although the study of identical twins is often preferred to
separate genetic and environmental factors, it is extremely rare.
More commonly, research on DNA methylation alterations in
AD involves unrelated participants discordant for AD. Both prior
to and since Mastroeni’s study in 2009, other groups have ana-
lyzed global DNA methylation in various brain regions of unre-
lated individuals discordant for AD.
Temporal cortex
As a follow-up to their twin study, Mastroeni et al. [82] used
immunohistochemistry to study DNA methylation in the ento-
rhinal cortex of a sample population with and without AD. Like
the conclusions drawn from their previous study, the authors
found that there was a significant decrease in global DNA meth-
ylation in individuals with AD compared to individuals without
AD. Importantly, immunoreactivity for 5mC was not signifi-
cantly different in relatively AD-spared regions such as the cer-
ebellum, suggesting that DNA methylation alterations in AD are
region-specific. Although the results of this study in combina-
tion with the results from the 2009 twin study might lead read-
ers to surmise that individuals with AD have lower levels of
DNA methylation in the temporal cortex than individuals with-
out AD, results from other studies using similar antibody-based
methods do not support this conclusion. In contrast, Coppieters
et al. [17] showed that there was an increase in the global DNA
methylation of brain tissue samples derived from the middle
temporal gyrus of subjects with AD compared with age-
matched, cognitively normal controls. Lashley et al. [86] found
that there was no significant difference in global DNA methyla-
tion in the entorhinal cortex of individuals with and without
AD [86].
Phipps et al. [87], recognizing that perhaps DNA methylation
could be cell-type specific, used immunohistochemistry to ana-
lyze 5mC and 5hmC in neuronal and glial cell types in the infe-
rior temporal gyrus of human AD cases and age-matched
controls. Results of their study suggest that extranuclear 5mC in
neurofilament-labeled pyramidal neurons, which are particu-
larly vulnerable to AD pathology [88–90], is significantly
decreased in AD cases compared with controls. This same trend
was seen in astrocytes. Interestingly, AD-spared calretinin
interneurons and microglia did not have significant alterations
in 5mC or 5hmC, which supports the hypothesis that DNA
methylation alterations in AD are dependent upon the particu-
lar cell type studied.
Frontal cortex
The frontal cortex is a site of significant synapse loss in AD [91,
92], and as such, it is often analyzed in AD studies. As men-
tioned previously, Mastroeni’s twin study found decrements in
DNA methylation in the frontal cortex of the twin with AD com-
pared with the cognitively-normal twin [85]. Since then, how-
ever, other studies using similar antibody-based methods have
found that individuals with AD tend to have a higher level of
DNA methylation than individuals without AD. Coppieters et al.
[93], for example, found that DNA methylation was higher in
the middle frontal gyrus of individuals with AD than in the
same region of age-matched controls. Similarly, Rao et al. [94]
also found increased global DNA methylation in the frontal cor-
tex of AD patients compared with cognitively-normal controls.
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Hippocampus
One of the hallmark pathologies of AD is cerebral atrophy, and
atrophy of the hippocampus, a region involved in memory for-
mation, is particularly severe. Thus, researchers have long been
analyzing the hippocampus as a brain region significantly
impacted by AD. Like the results of studies on DNA methylation
within the temporal cortex and frontal cortex, the results of
studies analyzing DNA methylation alterations within the hip-
pocampus are inconclusive. A study by Chouliaras et al. [95]
found a significant decrease in hippocampal DNA methylation
in AD cases compared to unrelated, age-matched controls. In
addition, the authors found that glial cell DNA methylation was
significantly different in the CA1 and CA3 subregions, whereas
neuronal DNA methylation was significantly different only in
the CA1 subregion, suggesting that cell type specific alterations
in DNA methylation vary depending on hippocampal subregion.
The same year that Chouliaras et al. published these results,
Bradley-Whitman et al. [96] also published a study analyzing
DNA methylation within the hippocampus. Interestingly,
they found the opposite: individuals with AD had higher levels
of DNA methylation in the hippocampus than individuals with-
out AD.
Gene-specific DNAmethylation alterations
in AD
To date, there have been several studies analyzing gene-specific
DNA methylation in brain tissue of patients with and without
AD [86, 94, 97–100]. Much like the results from studies analyzing
global DNA methylation, these studies have been inconclusive.
However, a number of common DNA methylation alterations in
specific genes have been observed across studies, providing rel-
atively strong evidence that methylation within these genes
may be altered in AD [98, 101, 102].
Genes related to AD pathology
Initially, studies of gene-specific DNA methylation differences in
AD focused on genes associated with AD pathology such as APP,
PSEN1, MAPT and apolipoprotein E (APOE). Barrachina et al. [103]
analyzed DNA methylation of APP, PSEN1 and MAPT in the frontal
cortex and hippocampus of non-demented control individuals
and individuals in various stages of AD and found no significant
differences in the DNA methylation in any of the three genes
studied. Iwata et al. [104] used pyrosequencing to analyze DNA
methylation of various CpG sites of AD-related genes in the infe-
rior temporal lobe, the superior parietal lobe and the cerebellum
in AD subjects and non-demented control subjects. They found
significant differences in DNA methylation profiles of APP, MAPT
and GSK3B, but not of PSEN1, BACE1 or APOE. Moreover, the
authors demonstrated that these alterations in DNA methylation
translated into changes in gene expression, which provides a
potential mechanism by which DNA methylation can impact the
AD phenotype in these subjects.
APOE is an apolipoprotein that associates with lipoproteins
in the plasma as a component of systemic lipid metabolism. In
addition, APOE is widely expressed in the central nervous sys-
tem and functions as the primary cholesterol carrier necessary
for the maintenance, growth and repair of neurons [105].
Importantly, APOE is reduced in the hippocampus of patients
with AD and is thought to enhance proteolytic degradation of
amyloidogenic Ab [105–107]. Moreover, a specific allele of APOE,
APOE-4, is significantly less effective at degrading Ab than the
other alleles [106]. APOE-4 is a risk factor for AD [108]; individu-
als homozygous for the APOE-4 allele are eight times as likely
to develop AD as individuals without the APOE-4 allele [108].
Using MALDI-TOF mass spectrometry in postmortem brain tis-
sue samples derived from the prefrontal cortex of individuals
with AD and matched controls, Wang et al. [109] found that the
promoter region of APOE, but not APP, was hypermethylated
individuals with AD.
In addition to the genes classically associated with AD,
numerous genome-wide association studies have identified
genetic variants associated with increased AD susceptibility,
including but not limited to sortilin-related receptor, low-
density lipoprotein receptor class A repeat-containing protein
(SORL1), ATP-binding cassette, sub-family A, member 7 (ABCA7),
and bridging integrator 1 (BIN1) [110–113]. Yu et al. [113] analyzed
DNA methylation in the dorsolateral prefrontal cortex of sub-
jects with and without AD at 28 gene loci associated with AD
pathology. Of the 28 gene loci, DNA methylation of five genes
(SORL1, ABCA7, HLA-DRB5, SLC2A4 and BIN1) was significantly
associated with pathological AD. SORL1 regulates recycling of
APP back into the cell, and in its absence, APP is instead directed
towards endosomal secretase cleavage pathways that generate
Ab [114, 115]. ABCA7 is primarily known for its role in lipid efflux
from cells to lipoprotein particles, but it has also been shown to
regulate APP processing, secretion and clearance [116–118].
Although there is relatively little known about the role of BIN1
in AD pathogenesis, it is hypothesized to primarily affect tau
pathology, APP endocytosis and intracellular trafficking, neuro-
inflammation and calcium transients [119]. Results from studies
such as those mentioned here suggest that alterations in DNA
methylation of AD-related genes are significantly associated
with AD pathology.
Genes related to neuroplasticity, memory formation and
neuroinflammation
Multiple genes involved in neuroplasticity and memory forma-
tion are differentially methylated between individuals with AD
and individuals without AD. Sanchez-Mut et al. [84] used a cus-
tomized Illumina VeraCode GoldenGate DNA Methylation array
to study DNA methylation of genes related to sensory percep-
tion, cognition, neuroplasticity, brain physiology and neurologi-
cal diseases in the frontal cortex of two transgenic mouse
models of AD (APP/PSEN1 and 3xTg-AD). The authors validated
the results of the array by pyrosequencing and found significant
DNA hypermethylation in various genes, including thrombox-
ane A2 receptor (Tbxa2r) and sorbin and SH3 domain containing
3 (Sorbs3). Tbxa2r encodes a G-protein coupled receptor that
modulates cAMP response-element binding protein (CREB),
which in turn is a transcription factor involved in neuronal plas-
ticity, long-term memory formation and neuroprotection [120].
The protein product of Sorbs3 is a scaffold protein that, among
other functions, modulates cell survival by regulating epidermis
growth factor-induced activation of c-jun N-terminal kinase
(JNK) [121, 122]. The results of Sanchez-Mut’s study were similar
to those of an earlier study that found hypermethylation within
SORBS3 in the temporal cortex of AD patients [31].
Mendioroz et al. [123] analyzed gene expression and methyl-
ation of CREB-regulated transcription factor 1 (CRTC1), a coacti-
vator of the CREB-dependent gene transcription pathway
involved in synaptic plasticity and long-term memory forma-
tion that is highly expressed in hippocampal neurons. CRTC1
was significantly hypomethylated in the hippocampus of indi-
viduals with AD compared with controls, and furthermore,
4 | Environmental Epigenetics, 2017, Vol. 3, No. 2
methylation within CRTC1 was inversely correlated with Ab and
phosphorylated tau expression. Also, the expression of CRTC1
mRNA was significantly lower in AD cases compared with con-
trols, and downstream target genes of CRTC1 were down regu-
lated, demonstrating that DNA hypomethylation within CRTC1
translated functionally into decreased transcriptional expres-
sion and downstream effects.
Neuroinflammation is commonly associated with AD [124–
126]. There is evidence that expression levels of IL-1b and IL-6
peak in the early stages of AD but return to more normal levels in
the later stages [127]. Since both IL-1b and IL-6 are modulated by
DNA methylation in various chronic diseases [128, 129], Nicolia et
al. [130] sought to determine whether or not DNA methylation in
the promoter region of these genes contributes to the fluctuation
in expression levels seen across AD stages. After analyzing DNA
methylation in the frontal cortex of patients with AD and
middle-aged controls using techniques based on bisulfite modifi-
cation, the authors found evidence of hypomethylation in the IL-
1b promoter in the early stages of AD that returned to middle-
aged control levels in later stages. In contrast, they found that IL-
6 methylation decreased with AD progression.
DNAmethylation in peripheral blood
Aberrant methylation in the peripheral blood is correlated with
AD disease status [131, 132], so some argue that peripheral blood
is a good indicator for AD-associated methylation changes when
brain tissue is not available. However, evidence concerning DNA
methylation differences in peripheral blood is inconclusive [133,
134]. As an example, brain-derived neurotrophic factor (BDNF), a
protein involved in neuronal survival, differentiation and plasti-
city, is often reduced in AD and is commonly analyzed in AD
studies [135–137]. Carboni et al. [138] found no significant differen-
ces in DNA methylation in the promoter region of BDNF in periph-
eral blood. On the other hand, Chang et al. [139] showed an
elevation of promoter BDNF DNA methylation in peripheral blood
samples of AD patients compared with gender- and age-matched
controls. Similarly, Nagata et al. [140] found that DNA methylation
of the BDNF promoter in peripheral blood mononuclear cells of
patients with AD was significantly higher than that of age-
matched cognitively normal controls. Importantly, percent meth-
ylation of certain CpG sites within the BDNF promotor correlated
negatively and significantly with neuropsychological test scores,
suggesting that BDNF promoter methylation is associated with
clinical manifestations of AD.
DNA hydroxymethylation in AD
Alteration of global 5hmC has been shown in a variety of neuro-
logical disorders such as Rett syndrome, autism spectrum disor-
der and Huntington’s disease [141–143]. It is not surprising,
then, that differences in 5hmC occur in AD as well, although the
differences appear to be region-specific. For instance, Condliffe
et al. [144] showed that there is a significant decrease in 5hmC
in the entorhinal cortex and cerebellum of individuals with AD
compared with their age-matched controls. Bradley-Whitman
et al. [96], who studied hydroxymethylation within the hippo-
campus and cerebellum, demonstrated that there is a signifi-
cant increase in 5hmC in the hippocampus, but not in the
cerebellum. In contrast to these results, Chouliaras et al. [95]
used immunohistochemistry to show that there was a 20.2%
reduction in 5hmC immunoreactivity in the hippocampus of AD
patients when compared with non-demented, age-matched
controls. Similar results were obtained when analyzing
monozygotic twins discordant for AD; 5hmC immunoreactivity
was 31.4% lower in the CA1 region of the hippocampus of the
AD twin compared with the non-demented twin. Coppieters et
al. [93] found that there was a significant increase in 5hmC in
the mid-frontal gyrus and mid-temporal gyrus of patients with
AD and further showed that 5hmC was relatively low in astro-
cytes and microglia, but high in neurons.
Evidence suggests that neurogenesis, which is associated
with alterations in hydroxymethylation, is altered in AD [145].
The subventricular zone (SVZ) and the subgranular zone are the
primary sites of neurogenesis in the aging brain [146]. It has
been hypothesized that neurogenesis decreases in the early
stages of AD but increases during later stages as part of a com-
pensatory mechanism [145, 147, 148]. Mastroeni et al. [149]
found an increase of 5hmC in the SVZ of AD patients compared
with non-diseased controls in vivo (brain tissue) and in vitro (pri-
mary SVZ cultures) using antibody-based methodologies. They
concluded that the compensatory increase in cell proliferation
in AD is linked to an increase in 5hmC.
Due to technological advancements in the area of 5hmC
high-throughput sequencing, studies have recently begun to
analyze gene-specific alterations in 5hmC in AD patients.
Bernstein et al. [150] analyzed genome-wide 5hmC in the pre-
frontal cortex of AD cases and then correlated this with tran-
scriptional changes using RNA-sequencing. They identified 325
genes containing differentially hydroxymethylated loci, of
which 140 displayed concomitant changes in gene expression.
The type of starting material used may impact the distribution
of 5hmC. A recent study by Shu et al. [65] using adult neural stem
cells shows that treatment with Ab decreased global 5hmC, sug-
gesting that Ab itself may have a direct impact on methylation.
Moreover, when comparing 5hmC levels in HEK293ft cells, adult
neural stem cells and neuronal tissue, they demonstrated that
5hmC is significantly higher in tissues than in cells. This suggests
that the type of starting material itself has an impact on DNA
hydroxymethylation. In addition, the authors characterized
changes in DNA hydroxymethylation associated with the interac-
tion between aging and AD by studying 5hmC levels in various
brain regions of wildtype mice and a transgenic AD mouse model
at 12 weeks of age and at 67 weeks of age. Although there were no
significant differences in DNA hydroxymethylation in either the
cortex or cerebellum with aging or with AD, there was a signifi-
cant difference between transgenic mice and wildtype mice in
the hippocampus at 67 weeks. It would appear, then, that brain
region is important when analyzing DNA hydroxymethylation
levels. Finally, the authors characterized the location of differen-
tially methylated 5hmC regions within the genome. These
regions were primarily located in gene bodies associated with
genes involved in neuronal development and function. More
studies like the one described above will further support a com-
plete understanding of 5hmC distribution and characterization.
Conclusions
Despite the surge of interest in DNA methylation and AD, evi-
dence is still inconclusive as to whether or not DNA methylation
or DNA hydroxymethylation is altered, particularly on a global
scale. Conflicting results have been reported for both types of
modifications. Additional studies measuring DNA methylation
and DNA hydroxymethylation both accurately and reproducibly
are needed before any conclusions can be reached. Numerous lim-
itations exist that impede progress in studying DNA methylation
in AD. For example, most studies on this topic predominately use
immunohistochemical approaches and/or microarray-based
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methods, such as the Illumina Infinium arrays, on small sample
sizes. Genomic coverage in these arrays is extremely limited;
Illumina’s Infinium HumanMethylation450 BeadChip array, for
example, interrogates only 1.5% of total CpG sites in the human
genome. Moreover, CpG sites included in the array are located pri-
marily in promoter regions, so relevant DNA methylation in gene
bodies is often missed. Whole-genome bisulfite sequencing
(WGBS), on the other hand, is able to analyze the entirety of a
genome at single-nucleotide resolution and is thus considered the
ideal methodology for DNA methylation studies. WGBS introduces
a whole host of other challenges, however. Currently, WGBS is
generally too expensive to run the large-scale studies needed to
account for interindividual variation seen in DNA methylation in
AD. Furthermore, there is no standardized method for analyzing
WGBS data. For these reasons, studying DNA methylation in AD
has been difficult, with studies often giving conflicting results.
Inconsistencies in the conclusions of studies reported here
could be due to any number of reasons. For instance, most stud-
ies on global methylation in AD are done in humans, which is
important for three reasons. First, it is extremely difficult to col-
lect the brain from a human subject exactly at the time of death,
and there is concern that the sample degrades during the time
between death and sample collection (postmortem interval).
Studies have shown, however, that DNA methylation is well
preserved in the postmortem brain for up to 48 h or even 72 h
[103, 151]. As the postmortem intervals recorded in most studies
are well below 48 h, sample degradation due to a long delay
between death and tissue processing does not account for the
variable results described here. Second, there is a naturally large
interindividual variation across human subjects, which can veil
anything but the most significant of differences. To further com-
plicate the matter, most human subject studies concerning DNA
methylation in AD use a relatively small sample size. The inher-
ently large interindividual variation across humans coupled with
the use of small sample sizes may bias the results of studies.
Third, AD is a complex, multifactorial disease that often presents
with heterogeneous pathologies. Hence, DNA methylation in AD
may depend largely on AD stage and pathological presentation.
Thus, conclusive results from human subject studies may be dif-
ficult to acquire, particularly in studies with small sample sizes.
In addition, the inconsistencies seen when analyzing DNA
methylation in AD could be due to a failure to recognize and
appreciate the complexity of the brain as an organ; the brain is
comprised of multiple regions and subregions, each with its
own function and unique DNA methylation profile [152]. In AD,
pathologies are often dependent upon brain region (e.g. the cer-
ebellum is relatively spared in AD pathogenesis). Thus, it would
be tempting to conclude that variation seen across studies could
be due to a lack of consistency in DNA methylation alterations
in AD across brain regions. As demonstrated in the studies pre-
sented in this review, however, there are differences even
between studies analyzing the same brain region. Importantly,
not only does the brain consist of numerous distinct regions,
each of these regions is also composed of numerous different
cell types. Cells are specialized with their own unique gene
expression and methylation signatures. Therefore, it is possible
that significant differences between methylation profiles could
be lost when cell types are analyzed together.
Finally, methodological differences could contribute to the
inconsistencies seen across studies. Earlier studies on DNA
methylation in AD use immunohistochemistry, a semi-
quantitative method that does not provide an accurate, quanti-
tative measurement of methylation or hydroxymethylation. In
addition, immunohistochemistry relies heavily on the
particular antibody probe being used; concerns about antibody
specificity must always be taken into account when comparing
studies using this method. More recent studies use methods
based on bisulfite conversion, in which unmethylated cytosines
are converted to uracils. Pyrosequencing and WGBS, both of
which are based on the process of bisulfite conversion, are con-
sidered gold standards for quantifying DNA methylation due to
their ability to measure DNA methylation at single-nucleotide
resolution. Despite this advantage, however, bisulfite conver-
sion does not distinguish between 5mC and 5hmC. This is a sig-
nificant problem for studying DNA methylation in AD, as 5hmC
is particularly abundant in the brain. In addition, because these
bisulfite-based methods are relatively new, standardized and
user-friendly software for analyzing bisulfite sequencing data
has only recently been developed. Thus, post-collection analy-
sis of data is different across studies, which could contribute to
the inconsistencies reported here. For more information regard-
ing the advantages and disadvantages of DNA methylation
analysis techniques, the reader is referred to excellent reviews
by Laird [153] and Kurdyukov et al. [154].
It is apparent that more research is needed to provide con-
clusive results. As the cost of WGBS decreases and the bioinfor-
matics software associated with WGBS analysis becomes more
user-friendly and widely available, it should become easier to
carry out large-scale studies on DNA methylation in the brain
and its association with AD. With further advancements in cell-
sorting and DNA methylation technology using small quantities
of sample, we should begin to see an increase in studies looking
at DNA methylation in specific cell types. In addition, studies
should focus on the interaction between the methylome, tran-
scriptome and the plethora of histone marks and non-coding
RNA in AD, as epigenetic modifications often work together to
achieve a particular phenotype [155]. Finally, the field should
consider: (i) using a combination of standard techniques such
as immunohistochemistry coupled with bisulfite sequencing
and (ii) comparing the results of genome-wide studies to focus
on common genes to improve comparability across studies. In
essence, although results are inconclusive, it is evident that the
environment, through its effect on DNA methylation, has an
impact on AD pathology. Thus, studies of epigenetic alterations
in AD will continue to be a topic of immense interest within the
research field.
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